CENTRAL TRUST Co lowered its position in Eli Lilly and Co (NYSE:LLY) by 2.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 59,727 shares of the company’s stock after selling 1,585 shares during the quarter. CENTRAL TRUST Co’s holdings in Eli Lilly and were worth $5,044,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Eli Lilly and by 2.3% in the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after purchasing an additional 1,610,885 shares during the period. BlackRock Inc. raised its position in Eli Lilly and by 2.1% in the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock valued at $5,232,942,000 after purchasing an additional 1,323,259 shares during the period. Janus Henderson Group PLC raised its position in Eli Lilly and by 16.1% in the third quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock valued at $928,719,000 after purchasing an additional 1,503,918 shares during the period. Dodge & Cox raised its position in Eli Lilly and by 22,094.9% in the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after purchasing an additional 5,964,955 shares during the period. Finally, Renaissance Technologies LLC raised its position in Eli Lilly and by 91.1% in the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after purchasing an additional 2,714,505 shares during the period. Hedge funds and other institutional investors own 76.20% of the company’s stock.
Eli Lilly and Co (NYSE LLY) opened at $77.03 on Thursday. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and Co has a 52 week low of $73.69 and a 52 week high of $89.09. The company has a market capitalization of $84,820.00, a P/E ratio of -385.15, a price-to-earnings-growth ratio of 1.42 and a beta of 0.23.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The company had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. During the same period in the previous year, the firm posted $0.95 earnings per share. Eli Lilly and’s quarterly revenue was up 7.0% compared to the same quarter last year. equities research analysts predict that Eli Lilly and Co will post 4.88 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a yield of 2.92%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s payout ratio is presently -1,040.00%.
A number of analysts have recently issued reports on LLY shares. Credit Suisse Group reaffirmed a “hold” rating and set a $80.00 target price on shares of Eli Lilly and in a research report on Friday, February 2nd. Bank of America dropped their target price on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, February 1st. BMO Capital Markets lifted their target price on Eli Lilly and from $73.00 to $74.00 and gave the stock an “underperform” rating in a research report on Thursday, February 1st. Jefferies Group set a $100.00 target price on Eli Lilly and and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Finally, Goldman Sachs Group lowered Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $86.98 to $95.00 in a research report on Tuesday, January 16th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $92.02.
In other news, insider Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the transaction, the insider now directly owns 4,130 shares in the company, valued at $334,901.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the transaction, the insider now owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 259,610 shares of company stock valued at $22,727,406. 0.20% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: “Eli Lilly and Co (LLY) Position Reduced by CENTRAL TRUST Co” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/15/eli-lilly-and-co-lly-stake-lowered-by-central-trust-co.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.